Celcuity Inc. (CELC) Reports mCRPC Combo Data; rPFS 15.7 Months Post-Abiraterone
Celcuity Inc. (CELC) reported Phase 1b/2 data for gedatolisib + darolutamide in mCRPC, showing median rPFS of 15.7 months post-abiraterone. Phase 2 trials are expected to begin in H1 2027. The data adds a new tumor setting to gedatolisib's program.
How this was made
The 30-second read
Why it matters
The trial shows median rPFS of 15.7 months post‑abiraterone, which is encouraging for a disease with limited options, potentially increasing the stock's upside.
Market read
First‑report trial data provide fresh material for traders; the positive efficacy signals could drive short‑term price appreciation.
What to watch
No safety data disclosed; regulatory timelines and competitive landscape remain uncertain.
Background
Celcuity is a clinical‑stage oncology company; gedatolisib is already approved for breast cancer, and this is its first reported data in prostate cancer.
Ticker impact
Celcuity Inc. released first‑report Phase 1b/2 data for its gedatolisib + darolutamide combo in metastatic castration‑resistant prostate cancer.
likely upward pressure as the market prices in the encouraging trial data
Phase 1b/2 data are the first disclosed efficacy numbers; biotech stocks typically react positively to early‑stage success.
Market effects
Adds supportive data to the broader oncology‑focused biotech sector, potentially lifting peers with similar targets.
Minimal regional effect; impact confined to US biotech investors.
Limited global relevance beyond biotech investors.
Counterpoint
The data are early‑stage and may not translate to Phase 3 success; investors could be cautious.
Key entities
- companyCelcuity Inc.
US‑listed biotech developing gedatolisib.
- drugGedatolisib
PI3K/mTOR inhibitor being tested in combination with darolutamide.
